Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Tisotumab vedotin-tftv |
| Synonyms | |
| Therapy Description |
Tivdak (tisotumab vedotin-tftv) is an antibody-drug conjugate consists of anti-tissue factor (TF) antibody and the cytotoxic agent monomethyl auristatin E (MMAE), which induces killing of tumor cells overexpressing tissue factor (PMID: 24371232, PMID: 31796521). Tivdak (tisotumab vedotin-tftv) is FDA approved fro use in patients with with recurrent or metastatic cervical cancer (FDA.gov). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Tisotumab vedotin-tftv | Tivdak | HuMax-TF-ADC|TF-011-MMAE | Tivdak (tisotumab vedotin-tftv) is an antibody-drug conjugate consists of anti-tissue factor (TF) antibody and the cytotoxic agent monomethyl auristatin E (MMAE), which induces killing of tumor cells overexpressing tissue factor (PMID: 24371232, PMID: 31796521). Tivdak (tisotumab vedotin-tftv) is FDA approved fro use in patients with with recurrent or metastatic cervical cancer (FDA.gov). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03245736 | Phase II | Tisotumab vedotin-tftv | Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors. | Completed | USA | GBR | 0 |
| NCT03657043 | Phase II | Tisotumab vedotin-tftv | A Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen (innovaTV 208) | Completed | USA | ITA | IRL | ESP | DNK | BEL | 0 |
| NCT04697628 | Phase III | Topotecan Gemcitabine Irinotecan Tisotumab vedotin-tftv Pemetrexed Disodium Vinorelbine | Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer (innovaTV 301) | Active, not recruiting | USA | SWE | POL | NOR | NLD | ITA | IRL | HUN | GBR | FRA | FIN | ESP | DNK | DEU | CZE | CAN | BRA | BEL | AUT | ARG | 7 |
| NCT06459180 | Phase III | Gemcitabine Irinotecan Tisotumab vedotin-tftv Pemetrexed Disodium Vinorelbine Topotecan SKB264 | A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20) | Recruiting | USA | SWE | POL | NOR | NLD | ITA | ISR | IRL | GRC | FIN | ESP | DNK | CHE | CAN | BRA | BEL | AUT | AUS | ARG | 7 |
| NCT03485209 | Phase II | Tisotumab vedotin-tftv | Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors | Recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | 1 |
| NCT03438396 | Phase II | Tisotumab vedotin-tftv | A Trial of Tisotumab Vedotin in Cervical Cancer | Completed | USA | SWE | ITA | ESP | DNK | DEU | CZE | BEL | 0 |
CKB BOOST